Personalized cell therapies offer hope for some of the toughest cancers

Dr. Robert Hariri Q&A

You might expect to find Dr. Robert Hariri strolling through the headquarters of Celularity, the biotechnology company he founded, outfitted in PPE and sterile paper slippers. But when…

We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?

The furthest along is a vaccine candidate co-developed by Pfizer, the U.S.-based pharmaceutical giant, and Valneva SE, a French biotech company. In March, the companies…

BeyondSpring Pharmaceuticals (BYSI) CEO Joins The Watch List

The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for…

9 Meters ahead of the rest in fight against celiac disease

Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective…

The next generation Covid-19 vaccines seeking a slice of the market

Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in…

Challenges and opportunities in gene therapy development

Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene…

Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French…

Stellanova, a ‘new star’ in the biotech constellation, hopes for bright future with $15.5M series A

The Houston-based preclinical biotech has raised a $15.5 million series A round led by Sporos Bioventures. The funding will go toward bringing Stellanova’s lead antibody…

Scynexis clinches FDA green light for vaginal yeast infection blockbuster-to-be

The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class…

Calliditas is Getting to the Heart of Berger’s Disease

But this orphan disease is one of the main reasons the team at Calliditas Therapeutics goes to work every day.

Biotech CEOs weigh in on post-Covid changes to the industry

At Fountain, specifically, recent advances in AI have enabled us to spearhead a new unbiased approach to drug discovery and development.  We are using this…

Why You Shouldn’t Rely on a COVID-19 Antibody Test to Determine Immunity

“However, the mere presence of antibodies to a virus does not necessarily mean an individual has protective immunity to reinfection,” Ian Chan, CEO of Boston-based biotech…

ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal

When Boehringer Ingelheim and OSE Immunotherapeutics teamed up in 2018 to develop OSE’s first-in-class checkpoint inhibitor, it was clear BI had high hopes for the…

Leyden Labs Targets Viral Families To Head Off Next Pandemic

While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that…

Interim Blinded Results Show Promise of Nanocrystalline Gold Treatment For Amyotrophic Lateral Sclerosis

Interim blinded data from an ongoing phase 2 clinical trial (NCT04098406) suggest treatment effect of catalytically active nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City,…

Scynexis Reports Positive Data on its Investigational Antifungal

“Candida albicans has been the prominent species causing vaginal yeast infections, however, we are seeing a notable shift in the etiology candidiasis with non-albicans Candida species…

The Placental Stem Cell Advantage

As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research…

You may be able to take a COVID-19 vaccine in a pill one day

A company called Vaxart is developing a COVID-19 vaccine that comes in the form of a tablet that could be stored at room temperature and even mailed to people at home.

Windtree Therapeutics Leverages Heart Failure Asset Istaroxime in Multiple Indications

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving…

Fore Biotherapeutics picks Philadelphia for global HQ, may add dozens of workers

The company spent roughly three months looking at potential locations for its global headquarters, including Boston and the Washington, D.C., region.

A ‘flyover’ biotech launches in Texas with four Ron DePinho-founded companies under its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San…

Get to Know Jonathan Rigby, Group CEO of Revolo Biotherapeutics

BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic diseases by achieving superior…

Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials

Scynexis announced in October that it submitted a new drug application to the FDA for ibrexafungerp for the treatment of vulvovaginal candidiasis. The target action date is…

Despite Many Candidates, Covid-19 Treatments Lag Behind Vaccines

A similar approach—a broad-spectrum antiviral in the form of a nasal spray—has been taken by Leyden Labs in the Netherlands, who recently struck a deal…

Next Generation of Covid-19 Vaccines Could Be Pill or Spray

The next generation of Covid-19 vaccines in development could come as a pill or a nasal spray and be easier to store and transport than…

COVID Innovations: Vaccines for Variants, Drone Deliveries, Print-Your-Own Shots, and More

Vaxart is among the first to take an oral COVID-19 vaccine into the clinic. “Making the vaccine is only part of the problem,” says CSO…

High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds

By measuring the functional MAPK activity of different RAS mutations, researchers have developed a method they believe could help identify patients with RAS-mutated cancers likely…

Celularity: Productizing Placental-Derived Stem Cells for Any Patient

Celularity is a clinical-stage biotechnology company focusing on the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically modified natural…

Clene, Inc. is making huge strides against MS, ALS, Parkinson’s Disease

Imagine a future where such diseases as Multiple Sclerosis, Lou Gehrig’s and Parkinson’s Disease can be controlled or stopped altogether.

The Dark Horse of the Vaccine Race May Be This French Biotech

The company, Valneva SE, has a vaccine that could be more variant-proof, giving it an edge over other shots in what may be an annual campaign…

Preparing a Pandemic Plan for Whatever Comes Our Way Next

Which is why OSE Immunotherapeutics is developing a vaccine that aims to be pan-coronavirus. The formulation for CoVepiT, which focuses on inducing a lasting T cell immune…

Pyxis debuts next-gen cancer ADCs from under Pfizer’s wing

After raising a monster $152 million in a series B round last month, Pfizer darling Pyxis Oncology is ready to share more details about what it’ll be…

An experimental gene therapy was little Alissa’s only hope. Now, instead of certain death, she faces an uncertain future.

Thomas Feldborg and Daria Rokina set off nearly every afternoon to explore this city. They leave from their hotel in the Charlestown neighborhood, pushing their…

Direct Listing vs. IPO

The company Richman leads, Gain Therapeutics, went public in March through an IPO. Regardless, he still thinks that going public through a SPAC is a…

Had It Been Covid-19 Oral Pill, More Americans Would Have Opted For Vaccination: Poll

A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine…

Antibody Structure: All You Ever Wanted – and Needed – to Know

“Differences in heavy chain polypeptides allow these immunoglobulins to function in different types of immune responses and at particular stages of the immune response. The…

Get to Know Norman Sussman, Chief Medical Officer at DURECT

BioSpace recently spoke with Norman Sussman, chief medical officer at DURECT, a company committed to transforming the treatment of acute organ injury and chronic liver diseases by…

Let’s Get to Know Paula Ragan, CEO and President of X4 Pharmaceuticals

BioSpace spoke with Paula Ragan, CEO and President of X4 Pharmaceuticals, a company focused on restoring healthy immune system function in people with rare diseases.…

The Making of a Gene Therapy for an Ultra-Rare Disease

While the since renamed company Sio Gene Therapies in-licensed one program in Parkinson’s disease, it also in-licensed a pair of gene therapy programs from the…

The placenta: a limitless source of stem cells?

US biotech firm Celularity is a leader in cell therapy development, and is focused on harnessing the therapeutic potential of cells contained in the postpartum placenta. Having…

Filling A Vaccine Void with Cue Biopharma’s Dan Passeri, J.D.

CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company’s Immuno-STAT platform for the selective targeting and alteration…

COVID-19 vaccines — minus the needle? Researchers working on capsules, nasal sprays

According to FasterCures, which is tracking 326 COVID-19 treatments and 252 vaccines, five companies are developing oral vaccines, and two — ImmunityBio and Vaxart —…

New name, new board, new focus: AltruBio relaunches with $63M series A

AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching…

New agonist MAb resolves chronic inflammation

A French study has demonstrated that the novel agonist anti-human ChemR23 monoclonal antibody (MAb) designated OSE-230 accelerated recovery from acute inflammation and triggered resolution of chronic inflammation…

mAb Manufacturing with Rezolute Bio’s Nevan Charles Elam, J.D.

Nevan Charles Elam, JD founded Rezolute Bio ten years ago on the heels of a complex career intersecting law, high tech, and life sciences. On…

The 20(+1) under 40: Inside the next generation of biotech leaders

How does one decide who makes an “under 40” list? After the last nominations come in from staff and readers, we’re left to sort through…

Bioprocessing Psilocybin for Mental Health

PsyBio Therapeutics, where Jones is chairman of the scientific advisory board, is commercializing the process. Jones and his team invented a one-pot method of bioprocessing with E. coli…

Rain Therapeutics tees up $100M IPO to push ex-Daiichi cancer drug into phase 3

Rain Therapeutics catapulted itself toward pivotal development in September when it picked up a cancer drug from Daiichi Sankyo. Now, the California biotech aims to…

After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B

It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to…

Biosynthesizing Psilocybin to Treat Mental Illness and Other Neurological Disorders with Evan Levine PsyBio Therapeutics

Evan Levine, Co-Founder and CEO, PsyBio Therapeutics is pursuing a paradigm shift in the treatment of mental illness and other neurological disorders by using psychedelics…

Yahoo Finance Presents: Dr. Patrick Soon-Shiong

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong sat down with Yahoo Finance’s Anjalee Khemlani to discuss the recent growth of ImmunityBio, it’s work on a vaccine…

Fierce Pharma Asia—Takeda’s Anima mRNA translation pact, China digital health incubator; Daiichi’s COVID-19 vaccine

Takeda penned a potentially billion-dollar deal with Anima Biotech to work on mRNA translation modulators for neurological diseases. The Japanese pharma also launched a digital…

GV wagers on seasoned team’s intranasal ‘temporary’ preventative approach to viruses — with ex-Gilead CEO John Martin jumping on board

Leyden Labs will focus on respiratory viruses with potential to cause pandemics, said Wiedhaup, who’s taking up the CEO role after a career spanning academia,…

Can gene therapy be made to work against solid tumours?

Oncosec have developed another way of delivering genes to tumour cells without the need for viral vectors or nanoparticles. They have taken advantage of the…

Durect hit? DNMT inhibitor may have found home in AH

With so many headlines touting drugs in development for the likes of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease, an illness in the same ballpark…

ProQR’s RNA therapy on track to pivotal tests in rare, inherited form of vision loss

ProQR Therapeutics has encouraging early data from a small study that show its experimental RNA-based therapy for a rare, inherited form of vision loss helped patients recover…

Targeting and Modulating CRAC Channels to Treat Acute Pancreatitis and COVID-19 with Dr. Sudarshan Hebbar CalciMedica

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order…

Clene is Using Nanocrystals of Pure Elements to Change Neurodegenerative Treatment

That is the mission of Clene Nanomedicine, which has combined cell biology, solid state physics, and materials science to pioneer the development of Clean-Surfaced Nanocrystal…

Chiasma posts data on benefits of oral acromegaly drug over long-acting injectable rivals

Chiasma has released phase 3 data supporting its belief that acromegaly patients will prefer to take its oral formulation over existing long-acting injectables.

Here’s what makes 4 promising COVID-19 vaccines unique — and potentially useful

How it works: The San Francisco–based company engineered a common cold virus called an adenovirus to carry instructions for making two coronavirus proteins into human cells.…

Anima Biotech Heads for the Light with Up-to-$2.4B Takeda Partnership

Anima specializes in treating targets long viewed as “undruggable” by targeting cellular mechanisms that regulate mRNA translation of proteins with specific biological roles in coordinating…

Protein misfolding specialist Gain nets $40m from IPO

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases…

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

Pyxis CEO Lara Sullivan has struck a deal with her former employer, Pfizer, that adds two preclinical therapies to the biotech’s pipeline as well as…

Takeda spreads it bets in Huntington’s

The Japanese company put down another marker in the disease today by teaming up with the private Israeli company Anima Biotech, in a transaction worth…

Immune Regulation’s Rebrand Reflects ‘Revolutionary’ Approach to Autoimmune Diseases

New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.

Anima Biotech and Takeda Enter Collab to Target mRNA Translation with Small Molecules

Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class…

Innovators target vaccines for variants and shortages in global South

The next generation of COVID-19 vaccines will not only tackle viral variants but also provide solutions across the globe at a fraction of the cost.

What is happening at Scotland’s Covid vaccine lab?

Biotech company Valneva is manufacturing a Covid-19 vaccine at its plant in West Lothian, which is currently going through clinical trials.

C&G Therapy Manufacturing Automation: Making The Most Of Today’s Opportunities

SOTIO — highlighted a variety of ways the industry could address the high cost of making these therapies. Despite the fact each of these experts…

Could a potential oral COVID vaccine be the new alternative to a vaccination shot?

If you’re not a fan of needles, how about a vaccine you take with a glass of water? That’s what San Francisco biotechnology company Vaxart…

Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells

Acepodia closed its Series B round Tuesday morning, hoping to build upon CEO Sonny Hsiao’s work from when he was a biologist at UC Berkeley.…